In this segment, Josh Wolfe, co-founder and managing partner at Lux Capital, introduces himself and shares his background in science and finance. He discusses his passion for investing in innovative technologies and life sciences, emphasizing the importance of proprietary knowledge and intellectual property in the ventures he supports.
"okay let's uh let's get going so uh thank you everybody for coming to our next virtual speaker series at the mit vcp club we have josh wolfe uh co-founder and managing partner at uh at lux capital in ..."
Josh Wolfe elaborates on his investment philosophy, focusing on 'outlier rebels'—individuals with unique backgrounds and experiences that drive them to innovate. He explains how personal struggles often lead to significant contributions to society, highlighting the value of diverse perspectives in the investment landscape.
"my own background is a hybrid of science and finance so i've always been obsessed with the endless frontier which is what science is the ability to you know find people who are quite literally inventi..."
Wolfe outlines Lux Capital's investment strategy, which is divided into three main areas: life sciences, energy and materials, and core technology. He discusses the firm's approach to identifying groundbreaking innovations and the types of companies they seek to support, including those in biotech, healthcare, and advanced technologies.
"society, because, i, think, it's, one, of the great drivers of progress so i like um you know finding out liar rebels and um outlier rebels who have a technical background the firm itself was formed a..."
In this segment, Josh Wolfe describes the different investment strategies employed by Lux Capital, including thesis-driven, people-driven, and special situations investments. He explains how these strategies allow the firm to capitalize on unique opportunities in the market and build strong relationships with entrepreneurs.
"everything from biotech to healthcare i.t to robotic surgery and med devices another third is in energy and materials uh often breakthroughs that were premised on some something in physics chemistry o..."
Josh shares his personal journey from a challenging upbringing in Coney Island to his path in investing. He reflects on his early interests in science and technology, his education at Cornell, and how his experiences shaped his perspective on human nature and the importance of innovation.
"2.4 billion under management handful of funds uh new york and menlo park headquartered and, we're, having, a lot, of, fun awesome i appreciate you hearing more background on the firm uh but would be g..."
Wolfe recounts how his fascination with science led him to explore capital markets during his time in a research lab. He discusses his transition from aspiring scientist to investment banker, highlighting the pivotal moments that directed him towards venture capital and the founding of Lux Capital.
"um i had a proclivity for science and sort of uh longing for anybody that was developing really futuristic crazy stuff part of that was probably psychologically you know me pining towards a better fut..."
In this segment, Josh Wolfe discusses the founding of Lux Capital with Peter Thiel and their vision for a new venture firm. He explains how they aimed to support innovative technologies beyond the traditional hubs of investment, focusing on overlooked talent and groundbreaking research across the country.
"science talent search which um i don't know who sponsors it now it's gone on you know intel siemens a variety of other companies usually whoever sponsoring it often pretends their imminent decline but..."
Wolfe shares insights into one of Lux Capital's significant investments, the acquisition of RS Health by Johnson & Johnson. He discusses the investment lifecycle, the role of key individuals in the company, and how the investment aligned with their thesis-driven approach.
"and um he is um just incredible sense of ethics and integrity and reputation so we've sort of always carried this mindset of what would bill do as we made you know really consequential and compounding..."
In this segment, Josh Wolfe explains the technological advancements in surgical procedures, particularly the shift towards minimally invasive techniques. He highlights the innovative ideas behind RS Health and how they represent the convergence of science fiction and reality in modern medicine.
"uh just really the life cycle of the investment yeah so part of that was born uh in a people driven investment and part of it was during the thesis driven investment the people happened to be an engin..."
In this segment, Wolfe explores the shrinking gap between science fiction and reality, using examples from popular culture to illustrate how futuristic concepts are becoming tangible technologies. He draws parallels between sci-fi narratives and real-world innovations, emphasizing the importance of visionary thinking in driving technological advancements.
"um but the the other piece of this which was very um satisfying was the science fiction element, and, one, of the, things, that, we hold here is that the gap between sci-fi and sci-fact keeps shrinkin..."
Wolfe offers valuable advice to MBA students at MIT on how to support researchers and founders in commercializing their projects. He emphasizes the importance of building relationships with commercially-minded principal investigators and fostering a collaborative environment to maximize the potential for successful startups.
"incredible team that had technology that nobody else had and frankly the timing where you know you really had two players in the industry um and a bunch of other players that were competing and pining..."
Wolfe discusses the significance of surrounding oneself with a strong network of peers and mentors in the entrepreneurial landscape. He highlights the importance of identifying and connecting with individuals who have the potential to become influential leaders in their fields, thereby enhancing opportunities for collaboration and success.
"investors yeah i mean really really great to hear and and, obviously you know you see it and it looks like the future and uh and it just keeps coming closer and closer to reality um you know for us as..."
In this segment, Wolfe contrasts the tech transfer strategies of MIT and Harvard, advocating for a portfolio approach to innovation. He explains how MIT's strategy encourages multiple attempts at commercialization, allowing for a greater chance of success in the competitive landscape of technology and healthcare.
"whatever it is um you know just sort of staying close to that cohort um the second thing is figuring out the pi's the principal investigators who are commercially minded so you know the mit in particu..."
Wolfe emphasizes the importance of identifying and collaborating with rising stars and protégés of established innovators. He shares insights on how to leverage relationships with influential figures in academia to foster new ventures and drive innovation in the healthcare sector.
"um when that happened i think the ability for uh reducing friction in somebody like bob to create a lot of companies would end up doing two things that would attract uh capital like us um you know pol..."
Wolfe reflects on the changing dynamics of scientific discovery and collaboration, noting how multiple researchers often work on similar projects simultaneously. He discusses the value of uniting these efforts under a single vision to create impactful companies, highlighting the importance of teamwork in advancing scientific innovation.
"learned from my late partner larry bach um it used to be that like something would get invented and the flow of information would generally accrue to one inventor even though the same thing might be d..."
In this engaging segment, Wolfe defends the relevance of science fiction in inspiring real-world technological advancements. He shares examples of how sci-fi concepts have influenced innovations in various fields, reinforcing the idea that imagination plays a crucial role in shaping the future of technology.
"piece of work that you know investors would find really valuable in pre-packaging a company yeah appreciate appreciate the response um we are going to open up to to questions so what would be easiest ..."
Wolfe discusses a unique healthcare investment inspired by groundbreaking research in optogenetics. He explains how this innovative approach aims to manipulate brain functions related to hunger and thirst, showcasing the potential for new treatments that bridge the gap between neuroscience and gastrointestinal health.
"from private equity background i personally i'm interested in inve you know sort of transitioning to early stage healthcare investing in particular and i look at kind of the funding dynamics today and..."
Wolfe explains the benefits of being an early investor in a market flooded with capital. He highlights how early-stage investments can create unique products that didn't exist before, and how risk reduction is key to value creation. This segment underscores the importance of identifying and funding innovative ideas before they become mainstream.
"that came out of voraciously reading and understanding what everybody else was doing, and, then, trying, to find, like what's the white space that nobody else is doing so in this moment there is an ab..."
In this segment, Wolfe emphasizes the critical role of storytelling in successfully launching new technologies. He draws parallels between compelling narratives and successful product launches, stressing that effective storytelling can capture attention and drive market acceptance. Wolfe also references influential books on persuasion and the importance of understanding human psychology in marketing.
"and i would you know be looking uh you know creating new companies with you know really singular uh scientists or or you know subsectors thank you great let's let's jump over to alex hey josh um so ac..."
Wolfe addresses the challenges of long-term investments in science and technology, explaining the distinction between a technology's success and a company's profitability. He shares insights from his experience with Control Labs, discussing how the perception of inevitability in technology can lead to successful investments, even if the technology itself is not yet fully developed.
"powerful skill thank you josh i'm just kidding i won't use your name uh okay uh raquel so thank you for having the time to talk to us um so i'm a from from a family of 15 physics phd so i kind of grew..."
Wolfe introduces a groundbreaking technology that allows users to control devices through gestures and neural signals, showcasing its potential to revolutionize human-computer interaction. He predicts that such innovations will become as commonplace as wearable technology, highlighting the importance of early adoption in gaming and beyond.
"but they also didn't want their competitors to own it so that's you know sort of how i would reconcile the time frames from a technology to really get out into the world mindful that what we're really..."
In this segment, Wolfe analyzes Facebook's need to develop its own hardware to enhance user experience and control. He compares Facebook's strategy to Amazon's successful integration of hardware with Alexa, suggesting that Facebook will eventually launch significant hardware products to establish a primary interface for users.
"in gaming you know you see um online advertisements now for um oculus quest where you know it's uh goggles and uh two handheld devices so that you can navigate over time those handheld devices will li..."
Wolfe shares insights on the evolving criteria for successful investments, emphasizing the importance of a strong team over technological superiority. He discusses how effective storytelling and the ability to attract talent can outweigh having the best technology, reshaping his investment philosophy.
"yeah that makes a lot of sense and amazon obviously something really well with alexa but i remember reading reports around them creating a phone so you know if you can't get hardware in one one area t..."
In this segment, Wolfe elaborates on the traits he looks for in founders, stressing the significance of passion and authenticity over generic ambitions. He describes the 'pampers effect'—the compelling presence of exceptional founders that draws others to them, highlighting the rarity of such individuals in the startup ecosystem.
"arguably their cost capital is lower and everything depends on cash so um now i put way more primacy on a team that can sell it's hard when we're making investments at the moment of inception or conce..."
Wolfe reflects on the difference between genuine ambition and performative statements about changing the world. He argues that true innovators are often singularly obsessed with their work, and this passion is what drives real change, contrasting it with those who merely claim to want to make an impact.
"met people like that where you're just like oh my god like this woman this guy are just amazing and um those people by definition are rare there's, a lot, of, people, that, fake, it um and you can usu..."
Wolfe discusses the current state of healthcare IT and the adoption of AI technologies, drawing parallels to historical trends in technology adoption. He highlights the importance of younger leaders in driving innovation and the potential for significant advancements in the healthcare sector through AI.
"for the time uh i know we have two more questions here so one from rez and then the last one will be from diego hey josh thanks for coming here with us today i actually want to ask you a question abou..."
In this closing segment, Wolfe addresses the potential for disruptive businesses to emerge from developing markets, particularly in Latin America. He explores the factors that contribute to technological adoption and the unique opportunities that may arise as these markets evolve.
"are more forward thinking tend to have younger chief data officers or chief data scientists or data scientists um that are ushering in you know the cooler stuff they're more familiar with and so that'..."
In this segment, Wolfe explores the potential for technological disruption in emerging markets, particularly in Latin America. He discusses the factors that contribute to faster tech adoption in developed countries and the unique challenges faced by businesses in emerging economies, including market structures and competition.
"think that there's value there interesting great so thanks josh for your time i was wondering like what's your view on them on every emerging markets in specific so i have like seen all the all the co..."
Wolfe highlights the rapid digital transformation in healthcare due to COVID-19, citing examples like Science 37, which revolutionized clinical trials. He discusses how the pandemic accelerated the adoption of technologies that improve efficiency and patient care in the healthcare sector.
"long-family-owned businesses um there's a conservatism that creeps in uh they might have dominant market share they might have sort of a you know tacit oligopoly between different players and so it ob..."
Wolfe introduces the concept of telepresence in surgical procedures, explaining how the company Avail is leveraging technology to enhance surgical expertise. He describes the innovative approach of using telepresence machines to allow medical device representatives to assist in surgeries remotely, improving efficiency and patient outcomes.
"to consumers are you selling to some you know larger segment of an industry and that's you know case-by-case basis nice thank you very much thank you i um i see there's one more hand so so perhaps we ..."
In this segment, Wolfe discusses Matterport, a company that specializes in rapid 3D scanning of physical spaces. He explains how this technology has gained traction in commercial real estate and insurance, particularly during the pandemic, enabling virtual property showings and enhancing the buying experience.
"and all these clinical trial sites were shut down they just went gangbusters like like just parabolic and um and that was a really interesting phenomenon because it was a exogenous shock that catalyze..."
Wolfe shares insights on the future of robotics and machine vision, emphasizing the potential for advancements in satellite identification and servicing. He discusses the market risks and opportunities in this field, highlighting the need for innovative solutions that can operate in complex environments.
"showings so those are sort of uh a few interesting ones one piece of unsolicited advice particularly if you're in robotics and machine vision it's still early and there's huge market risk but i haven'..."
Wolfe concludes by inviting entrepreneurs interested in joining Lux Capital to reach out. He emphasizes the firm's openness to connecting with individuals across various roles in their portfolio companies, showcasing Lux's commitment to fostering innovation and collaboration in the tech and investment space.
"robotics thank you appreciate it great well thank you to everybody who asked questions and and josh really appreciate your time here uh you know for people in the club that are interested in starting ..."